Gilead Sciences (GILD) May weekly option implied volatility bid into Q1 and outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Gilead Sciences (GILD) PT Lowered to $81 at Morgan Stanley
May 2, 2018 7:45 AM EDTMorgan Stanley lowered its price target on Gilead Sciences (NASDAQ: GILD) to $81.00 (from $85.00) while maintaining a Equalweight rating following the company's 1Q earnings report.
1Q18 EPS missed by $0.17. The miss was driven by lower than expected total revenues ($5.1B vs. $5.4B... More
